MINERALYS THERAPEUTICS INC. - COMMON STOCK

Mineralys Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update

15 5 2023 15:01:00 提供 Nasdaq GlobeNewswire

Mineralys Therapeutics Announces First Patient Dosed in the ADVANCE-HTN Pivotal Trial of Lorundrostat for the Treatment of Uncontrolled and Resistant Hypertension

02 5 2023 07:00:02 提供 Nasdaq GlobeNewswire

Mineralys Therapeutics to Announce First Quarter 2023 Financial Results and Host Conference Call on Monday, May 15, 2023

01 5 2023 07:00:02 提供 Nasdaq GlobeNewswire

Mineralys Therapeutics to Participate in the Bank of America Securities 2023 Health Care Conference on Wednesday, May 10, 2023

27 4 2023 15:47:56 提供 Nasdaq GlobeNewswire

Mineralys Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

15 3 2023 15:01:00 提供 Nasdaq GlobeNewswire

Mineralys Therapeutics Presents Positive Lorundrostat Results from the Phase 2 Target-HTN Trial at ACC.23/WCC

04 3 2023 15:30:00 提供 Nasdaq GlobeNewswire

Mineralys Therapeutics to Announce Fourth Quarter 2022 Financial Results and Host Conference Call on Wednesday, March 15, 2023

01 3 2023 15:05:01 提供 Nasdaq GlobeNewswire

Mineralys Therapeutics Abstracts Selected to be Presented at the American College of Cardiology Annual Scientific Session & Expo Together with the World Congress of Cardiology (ACC.23/WCC) in March 2023

20 2 2023 07:00:00 提供 Nasdaq GlobeNewswire

Mineralys Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

14 2 2023 15:01:00 提供 Nasdaq GlobeNewswire